Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
- PMID: 23831709
- DOI: 10.1038/nbt.2621
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
Abstract
By enabling the simultaneous engagement of two distinct _targets, bispecific antibodies broaden the potential utility of antibody-based therapies. However, bispecific-antibody design and production remain challenging, owing to the need to incorporate two distinct heavy and light chain pairs while maintaining natural nonimmunogenic antibody architecture. Here we present a bispecific-antibody production strategy that relies on co-culture of two bacterial strains, each expressing a half-antibody. Using this approach, we produce 28 unique bispecific antibodies. A bispecific antibody against the receptor tyrosine kinases MET and EGFR binds both _targets monovalently, inhibits their signaling, and suppresses MET and EGFR-driven cell and tumor growth. Our strategy allows rapid generation of bispecific antibodies from any two existing antibodies and yields milligram to gram quantities of bispecific antibodies sufficient for a wide range of discovery and preclinical applications.
Comment in
-
Bispecific antibodies with native chain structure.Nat Biotechnol. 2014 Feb;32(2):136-7. doi: 10.1038/nbt.2812. Nat Biotechnol. 2014. PMID: 24509759 No abstract available.
Similar articles
-
Bispecific antibodies with native chain structure.Nat Biotechnol. 2014 Feb;32(2):136-7. doi: 10.1038/nbt.2812. Nat Biotechnol. 2014. PMID: 24509759 No abstract available.
-
Impact of Cell-surface Antigen Expression on _target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.J Biol Chem. 2015 Oct 9;290(41):24689-704. doi: 10.1074/jbc.M115.651653. Epub 2015 Aug 10. J Biol Chem. 2015. PMID: 26260789 Free PMC article.
-
A novel glycoengineered bispecific antibody format for _targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19. J Biol Chem. 2014. PMID: 24841203 Free PMC article.
-
The use of CrossMAb technology for the generation of bi- and multispecific antibodies.MAbs. 2016 Aug-Sep;8(6):1010-20. doi: 10.1080/19420862.2016.1197457. Epub 2016 Jun 10. MAbs. 2016. PMID: 27285945 Free PMC article. Review.
-
Engineering therapeutic bispecific antibodies using CrossMab technology.Methods. 2019 Feb 1;154:21-31. doi: 10.1016/j.ymeth.2018.11.008. Epub 2018 Nov 16. Methods. 2019. PMID: 30453028 Review.
Cited by
-
Promise and challenges on the horizon of MET-_targeted cancer therapeutics.World J Biol Chem. 2015 May 26;6(2):16-27. doi: 10.4331/wjbc.v6.i2.16. World J Biol Chem. 2015. PMID: 26009700 Free PMC article.
-
Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.Front Immunol. 2016 Oct 6;7:394. doi: 10.3389/fimmu.2016.00394. eCollection 2016. Front Immunol. 2016. PMID: 27766096 Free PMC article. Review.
-
Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices.Nat Commun. 2020 Oct 2;11(1):4974. doi: 10.1038/s41467-020-18477-7. Nat Commun. 2020. PMID: 33009381 Free PMC article.
-
Advances in Antibody Design.Annu Rev Biomed Eng. 2015;17:191-216. doi: 10.1146/annurev-bioeng-071114-040733. Epub 2015 Aug 14. Annu Rev Biomed Eng. 2015. PMID: 26274600 Free PMC article. Review.
-
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.AMB Express. 2016 Dec;6(1):32. doi: 10.1186/s13568-016-0201-4. Epub 2016 Apr 26. AMB Express. 2016. PMID: 27112931 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous